A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Patients With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma (NCT02257567)
This study is a multicenter, open-label study of polatuzumab vedotin (DCDS4501A or RG-7596) administered by intravenous (IV) infusion in combination with standard doses of bendamustine (B) and rituximab (R) or obinutuzumab (G) in patients with relapsed or refractory follicular lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL). The study comprises two stages: a Phase Ib dose-escalation stage and a Phase II stage. The anticipated time on treatment is 18-24 weeks.
This trial is sponsored by Hoffmann-La Roche.
- Follicular Lymphoma
- B-Cell Lymphoma
- Non-Hodgkin’s Lymphoma
- Phase: II
- Estimated Enrollment: 225
- Start: October 2014
- Estimated Completion: June 2019
- Last verified: November 2017
Last Editorial review: December 19, 2017
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.
Copyright © 2015-2017 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.